DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Fundamental Analysis
Canada - TSX-V:GSD - CA2518348008 - Common Stock
0.17 CAD
+0.02 (+13.33%)
Taking everything into account, GSD scores 3 out of 10 in our fundamental rating. GSD was compared to 31 industry peers in the Pharmaceuticals industry. While GSD seems to be doing ok healthwise, there are quite some concerns on its profitability. GSD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GSD has reported negative net income.
In the past year GSD had a positive cash flow from operations.
GSD had negative earnings in each of the past 5 years.
GSD had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
GSD's Return On Assets of -22.47% is on the low side compared to the rest of the industry. GSD is outperformed by 67.74% of its industry peers.
With a Return On Equity value of -58.41%, GSD is not doing good in the industry: 61.29% of the companies in the same industry are doing better.
With an excellent Return On Invested Capital value of 8.78%, GSD belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.47% | ||
| ROE | -58.41% | ||
| ROIC | 8.78% |
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GSD's Operating Margin of 3.30% is fine compared to the rest of the industry. GSD outperforms 74.19% of its industry peers.
GSD has a Gross Margin of 37.10%. This is comparable to the rest of the industry: GSD outperforms 54.84% of its industry peers.
In the last couple of years the Gross Margin of GSD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.3% | ||
| PM (TTM) | N/A | ||
| GM | 37.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
2. Health
2.1 Basic Checks
GSD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for GSD has been increased compared to 1 year ago.
GSD has more shares outstanding than it did 5 years ago.
GSD has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.93, we must say that GSD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GSD (0.93) is better than 70.97% of its industry peers.
The Debt to FCF ratio of GSD is 0.02, which is an excellent value as it means it would take GSD, only 0.02 years of fcf income to pay off all of its debts.
GSD's Debt to FCF ratio of 0.02 is amongst the best of the industry. GSD outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that GSD is not too dependend on debt financing.
The Debt to Equity ratio of GSD (0.01) is better than 80.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.02 | ||
| Altman-Z | 0.93 |
ROIC/WACC1.12
WACC7.84%
2.3 Liquidity
GSD has a Current Ratio of 1.12. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.12, GSD is doing worse than 74.19% of the companies in the same industry.
A Quick Ratio of 1.12 indicates that GSD should not have too much problems paying its short term obligations.
GSD has a Quick ratio (1.12) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
GSD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.37%.
The Revenue has grown by 237.82% in the past year. This is a very strong growth!
The Revenue has been growing by 26.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GSD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GSD is valued a bit cheaper than the industry average as 77.42% of the companies are valued more expensively.
GSD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GSD is cheaper than 96.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.31 | ||
| EV/EBITDA | 8.77 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
GSD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:GSD (10/31/2025, 7:00:00 PM)
0.17
+0.02 (+13.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.65%
Ins Owner ChangeN/A
Market Cap27.88M
Revenue(TTM)32.94M
Net Income(TTM)-5159100
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.85 | ||
| P/FCF | 3.31 | ||
| P/OCF | 3.3 | ||
| P/B | 3.16 | ||
| P/tB | 7.09 | ||
| EV/EBITDA | 8.77 |
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.05
FCFY30.19%
OCF(TTM)0.05
OCFY30.26%
SpS0.2
BVpS0.05
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.47% | ||
| ROE | -58.41% | ||
| ROCE | 12.19% | ||
| ROIC | 8.78% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 3.3% | ||
| PM (TTM) | N/A | ||
| GM | 37.1% | ||
| FCFM | 25.54% |
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
F-Score6
Asset Turnover1.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.02 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 493.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 0.93 |
F-Score6
WACC7.84%
ROIC/WACC1.12
Cap/Depr(3y)3.28%
Cap/Depr(5y)2.81%
Cap/Sales(3y)1.16%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y137.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y296.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y297.04%
OCF growth 3YN/A
OCF growth 5YN/A
DEVONIAN HEALTH GROUP INC / GSD.CA FAQ
What is the fundamental rating for GSD stock?
ChartMill assigns a fundamental rating of 3 / 10 to GSD.CA.
What is the valuation status for GSD stock?
ChartMill assigns a valuation rating of 2 / 10 to DEVONIAN HEALTH GROUP INC (GSD.CA). This can be considered as Overvalued.
Can you provide the profitability details for DEVONIAN HEALTH GROUP INC?
DEVONIAN HEALTH GROUP INC (GSD.CA) has a profitability rating of 2 / 10.
How financially healthy is DEVONIAN HEALTH GROUP INC?
The financial health rating of DEVONIAN HEALTH GROUP INC (GSD.CA) is 5 / 10.